EBR Systems Inc. (ASX: EBR) is a small-cap ASX healthcare stock.
It is a clinical stage company that has developed its patented Wireless Stimulation Endocardial (WiSE) technology. The technology is for the treatment of cardiac rhythm disease. Specifically, it aims to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation Therapy (CRT).
It's worth noting that investors in clinical-stage companies should adopt a long-term focus on small-cap companies like this.
Meaningful returns often depend on multi-year clinical, regulatory, and commercial milestones that can progress slowly and unpredictably.
With that being said, the team at Morgans has identified EBR systems as an ASX healthcare stock with plenty to be optimistic about.
The broker has a buy recommendation and attractive price target on EBR systems shares.
Image source: Getty Images
Positive feedback
A note out of Morgans yesterday said feedback from the recently concluded Asia Pacific Heart Rhythm Society (APHRS) conference highlighted a meaningful shift in physician sentiment where confidence in conduction system pacing (CSP) for heart failure appears to be cooling following the PhysioSync-HF trial, reinforcing CRT's position as the superior therapy.
We believe US physicians with early commercial WiSE experience are increasingly likely to focus on de novo applications, which may accelerate market expansion beyond previously untreatable CRT patients.
These developments support our view that WiSE remains uniquely positioned in the evolving pacing landscape, with strengthening clinical pull-through and expanding addressable markets.
Overall, these trends reinforce that WiSE is well positioned in the shifting pacing landscape. Particularly with growing clinical demand and a widening market opportunity.
Attractive price target for this ASX healthcare stock
The team at Morgans has a buy rating on EBR systems shares with a price target of $2.86.
Based on yesterday's closing share price of $1.07, this indicates an upside of more than 160%.
Morgans aren't the only broker optimistic on this ASX healthcare stock.
In a report from Bell Potter last week, the broker said EBR's early commercial rollout is showing strong momentum.
EBR reported a tripling in quarterly revenue to c.US$0.51m and Gross Profit to c.US$0.22m in 3Q25 as pre-reimbursement commercial activity picked up momentum.
The broker also said a number of data points show an encouraging early trend in the commercialisation launch.
For these reasons we believe consensus revenue estimates of c.US$15.7m in FY26 are low and expect upgrades to follow.
The team at Bell Potter also has a recommendation on this ASX healthcare stock with a price target of $2.43.
